In our study, the derivative AML cell lines that became resistant to venetoclax after long-term exposure showed decreased BCL2 dependency while retaining sensitivity to MCL1i and/or acquired sensitivity to BCL-xLi. The gene discussed is BCL2; the disease is acute myeloid leukemia.